Optimization of the heterocyclic core of the quinazolinone-derived CXCR3 antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 2, 2008, Pages 688-693

  Li, An Rong ^a   Johnson, Michael G ^a   Liu, Jiwen ^a   Chen, Xiaoqi ^a   Du, Xiaohui ^a   Mihalic, Jeffrey T ^a   Deignan, Jeffrey ^a   Gustin, Darin J ^a   Duquette, Jason ^a   Fu, Zice ^a   Zhu, Liusheng ^a   Marcus, Andrew P ^a   Bergeron, Phillipe ^a   McGee, Lawrence R ^a   Danao, Jay ^a   Lemon, Bryan ^a   Carabeo, Teresa ^a   Sullivan, Timothy ^a   Ma, Ji ^a   Tang, Liang ^a   Tonn, George ^a   Collins, Tassie L ^a   Medina, Julio C ^a   more..

^a AMGEN INC   (United States)

Author keywords

Chemokine; CXCL10; CXCL11; CXCL9; CXCR3; IP10; ITAC; Mig

Indexed keywords

1,8 NAPHTHYRIDINE DERIVATIVE; 8 AZAQUINAZOLINONE DERIVATIVE; AMG 487; BENZIMIDAZOLE; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR3 ANTAGONIST; FUSED HETEROCYCLIC RINGS; IMIDAZOPYRIDINE DERIVATIVE; NAPHTHYRIDINE DERIVATIVE; PYRIDOPYRIMIDINE; PYRIMIDINE DERIVATIVE; QUINAZOLINONE DERIVATIVE; QUINOLINE; QUINOXALINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CELL MIGRATION; DRUG ACTIVITY; DRUG METABOLISM; DRUG POTENCY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IMMUNOMODULATION; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HETEROCYCLIC COMPOUNDS; HUMANS; QUINAZOLINONES; RATS; RECEPTORS, CXCR3; STEREOISOMERISM;

EID: 38149133179     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.11.060     Document Type: Article

References (24)

1. Cather J.C., and Menter A. Exp. Opin. Biol. Ther. 3 (2003) 361
2. Gottlieb A.B., Krueger J.G., Wittkowski K., Dedrick R., Walicke P.A., and Garovoy M. Arch. Dermatol. 138 (2002) 591
3. Ghosh S., Goldin E., Gordon F.H., Malchow H.A., Rask-Madsen J., Rutgeerts P., Vyhnalek P., Zadorova Z., Palmer T., and Donoghue S. N. Engl. J. Med. 348 (2003) 24
4. Miller D.H., Khan O.A., Sheremata W.A., Blumhardt L.D., Rice G.P., Libonati M.A., Willmer-Hulme A.J., Dalton C.M., Miszkiel K.A., and O'Connor P.W. N. Engl. J. Med. 348 (2003) 15
5. Medina J., Johnson M.G., and Collins T.L. Ann. Reports Med. Chem. 40 (2005) 215
6. Collins T.L., Johnson M.G., and Medina J.C. In: Neote K., Letts G.L., and Moser B. (Eds). Chemokine Biology-Basic Research and Clinical Application Vol. 2 (2007), Birkhauser Verlag Publishers 79
7. Yuan Y.H., ten Hove T., The F.O., Slors J.F., van Deventer S.J., and te Velde A.A. Inflamm. Bowel Dis. 7 (2001) 281
8. Uguccioni M., Gionchetti P., Robbiani D.F., Rizzello F., Peruzzo S., Campieri M., and Baggiolini M. Am. J. Pathol. 155 (1999) 331
9. Mahad D.J., Howell S.J., and Woodroofe M.N. J. Neurol. Neurosurg. Psychiatry 72 (2002) 498
10. Mahad D.J., Lawry J., Howell S.J., and Woodroofe M.N. Mult. Scler. 9 2 (2003) 189
11. Sorensen T.L., Tani M., Jensen J., Pierce V., Lucchinetti C., Folcik V.A., Qin S., Rottman J., Sellebjerg F., Strieter R.M., Frederiksen J.L., and Ransohoff R.M. J. Clin. Invest. 103 (1999) 807
12. Sorensen T.L., Trebst C., Kivisakk P., Klaege K.L., Majmudar A., Ravid R., Lassmann H., Olsen D.B., Strieter R.M., Ransohoff R.M., and Sellebjerg F. J. Neuroimmunol. 127 (2002) 59
13. Gottlieb A.B., Luster A.D., Posnett D.N., and Carter D.M. J. Exp. Med. 68 (1988) 941
14. Rottman J.B., Smith T.L., Ganley K.G., Kikuchi T., and Krueger J.G. Lab Invest. 81 (2001) 335
15. Patel D.D., Zachariah J.P., and Whichard L.P. Clin. Immunol. 98 (2001) 39
16. Melter M., Exeni A., Reinders M.E., Fang J.C., McMahon G., Ganz P., Hancock W.W., and Briscoe D.M. Circulation 104 (2001) 2558
17. Segerer S., Cui Y., Eitner F., Goodpaster T., Hudkins K.L., Mack M., Cartron J.P., Colin Y., Schlondorff D., and Alpers C.E. Am. J. Kidney Dis. 37 (2001) 518
18. Agostini C., Calabrese F., Rea F., Facco M., Tosoni A., Loy M., Binotto G., Valente M., Trentin L., and Semenzato G. Am. J. Pathol. 158 (2001) 1703
19. Johnson M., Li A., Liu J., Fu Z., Zhu L., Miao S., Wang X., Xu Q., Huang A., Marcus A., Xu F., Ebsworth K., Sablan E., Danao J., Kumer J., Dairaghi D., Lawrence C., Sullivan T., Tonn G., Schall T., Collins T., and Medina J. Bioorg. Med. Chem. Lett. 17 12 (2007) 3339
20. Allen D.R., Bolt A., Chapman G.A., Knight R.L., Meissner J.W.G., Owen D.A., and Watson R.J. Bioorg. Med. Chem. Lett. 17 3 (2007) 697
21. Storelli S., Verzijl D., Al-Badie J., Elders N., Bosch L., Timmerman H., Smit M.J., De Esch I.J.P., and Leurs R. Archiv der Pharmazie 340 6 (2007) 281
22. Cole A.G., Stroke I.L., Brescia M.-R., Simhadri S., Zhang J.J., Hussain Z., Snider M., Haskell C., Ribeiro S., Appell K.C., Henderson I., and Webb M.L. Bioorg. Med. Chem. Lett. 16 1 (2006) 200
23. 125I]-IP10 binding assay in buffer with the exception that EDTA-anti-coagulated human plasma ("plasma") was added to the assay buffer, to 50% final assay concentration. ITAC in vitro cell migration assay: 100 ng/ml of human ITAC resuspended in 100% plasma was added to the lower chamber of a migration plate. Human PBMC (prepared as above) were resuspended in 100% plasma and placed in the upper chamber of the migration plate. Compounds were measured for their ability to inhibit CXCR3 mediated migration of cells into the lower chamber, in response to ITAC.
24. Dancer J.E., Ford M.J., Hamilton K., Kilkelly M., Lindell S.D., O'Mahony M.J., and Saville-Stones E.A. Bioorg. Med. Chem. Lett. 6 17 (1996) 2131